The sickest-first principle in donor-liver allocation can be implemented by allocating organs to patients with cirrhosis with the highest Model for End-Stage Liver Disease (MELD) scores. For patients with other risk factors, standard exceptions (SEs) and nonstandard exceptions (NSEs) have been developed. We investigated whether this system of matched MELD scores achieves similar outcomes on the liver transplant waiting list for various diagnostic groups in Eurotransplant (ET) countries with MELD-based individual allocation (Belgium, the Netherlands, and Germany). A retrospective analysis of the ET wait-list outflow from December 2006 until December 2015 was conducted to investigate the relation of the unified MELD-based allocation to the risk of a negative wait-list outcome (death on the waiting list or delisting as too sick) as opposed to a positive wait-list outcome (transplantation or delisting as recovered). A total of 16,926 patients left the waiting list with a positive (11,580) or negative (5346) outcome; 3548 patients had a SE, and 330 had a NSE. A negative outcome was more common among patients without a SE or NSE (34.3%) than among patients with a SE (22.6%) or NSE (18.6%; P < 0.001). Analysis by model-based recursive partitioning detected 5 risk groups with different relations of matched MELD to a negative outcome. In Germany, we found the following: (1) no SE or NSE, SE for biliary sepsis (BS); (2) SE for hepatocellular carcinoma (HCC), hepatopulmonary syndrome (HPS), or portopulmonary hypertension (PPH); and (3) SE for primary sclerosing cholangitis (PSC) or polycystic liver disease (PcLD). In Belgium and the Netherlands, we found the following: (4) SE or NSE, or SE for HPS or PPH; and (5) SE for BS, HCC, PcLD, or PSC. In conclusion, SEs and NSEs do not even out risks across different diagnostic groups. Patients with SEs or NSEs appear advantaged toward patients with cirrhosis without SEs or NSEs.
of donor organs in relation to demand. Therefore, measures for prioritization based "solely on objective medical criteria that are applied fairly and are open to public examination" (1) were implemented with the introduction of formalized systems of donor organ distribution. The Model for End-Stage Liver Disease (MELD) is a prospectively developed and validated scoring system for cirrhosis that uses a patient's laboratory values for serum bilirubin, serum creatinine, and the international normalized ratio (INR) for prothrombin time to predict 3-month survival. (2) MELD score thus provides a stratification of patients with cirrhosis according to the severity of disease and allocation corresponding to the sickest-first principle or medical urgency is realized by allocation according to the MELD score. However, the laboratory MELD may not adequately reflect mortality risk of hepatobiliary conditions different from cirrhosis that are also indications for liver transplantation.
For such conditions MELD score "standard exceptions" (SEs) have been modeled to render the respective mortality risks comparable with the mortality risk of patients with cirrhosis by expressing them in MELD score equivalents that are referred to as "exceptional MELD." (3) For these patients, the higher value of either laboratory MELD or exceptional MELD is used for organ allocation. It is called matched MELD.
According to clinical criteria, groups of patients are defined, who are awarded exceptional matched MELD scores either by allotting a fixed amount of points, by assigning exceptional MELD scores that automatically increase every 3 months for as long as the justifying condition persists, or by entitling patients to a percent increase on their laboratory MELD score. For rare conditions or individual patients who are not well represented by the system of laboratory MELD and SE, nonstandard exceptions (NSEs) have been introduced that award MELD score equivalents after an informal audit process has been passed.
In order to be consistent with this urgency-based allocation, the resulting risk of a negative wait-list outcome should be similar for all patients across diagnostic groups independent of their qualification for SEs or NSEs.
Recent reports from the United States, however, indicate that at least some MELD exceptions may overcompensate in relation to real mortality risk and may unintentionally favor patients with certain conditions. Among those, numerically the most important group are patients with hepatocellular carcinoma (HCC), resulting at the same time in reduced wait-list mortality for HCC patients compared with patients with cirrhosis alone, and increasing MELD scores at allocation for all patients. This development has been denounced as MELD score inflation and reflects the automatic timedependent increments in allotted MELD points for HCC that apparently are not paralleled by equivalent increases in mortality risk. (4) (5) (6) We examined if the system of SEs and NSEs succeeds in equalizing the risk of a negative outcome on the waiting list across different disease entities in the Eurotransplant (ET) MELD countries Germany, Belgium, and the Netherlands, where MELD score-based allocation of donor livers was introduced in December 2006.
Patients and Methods

MELD-BASED INDIVIDUAL ALLOCATION IN THE ET AREA
The ET International Foundation is a Dutch nonprofit organization that organizes multinational transplant organ allocation for its member countries comprising Austria, Belgium, Croatia, Germany, Hungary, Luxembourg, the Netherlands, and Slovenia.
MELD-based allocation was introduced in the ET-MELD countries in December 2006 guided by a common regulatory manual that defined MELD exceptions for HCC, polycystic liver disease (PcLD), primary hyperoxaluria, hepatoblastoma, persistant hepatic (graft) dysfunction, cystic fibrosis, familial amyloidotic polyneuropathy, hepatopulmonary syndrome (HPS), urea cycle disorders, or cholangiocarcinoma. Only in 3 countries, Belgium, Germany, and the Netherlands, is MELD-based allocation directly to the individual patient, whereas in the other countries, organs are allocated to the centers.
In 2008, MELD exceptions were added for primary sclerosing cholangitis (PSC; in Germany only), portopulmonary hypertension (PPH), hereditary hemorrhagic telangiectasia (HHT), hepatic hemangioendothelioma (HEHE), and biliary sepsis (BS)/ secondary sclerosing cholangitis. Exceptional MELD criteria and the awarded exceptional MELD scores for all ET countries are listed in the ET liver allocation manual. (7) Briefly, in order to be granted exceptional MELD scores, certain criteria have to be fulfilled for each condition (eg, a T2 tumor stage for HCC or 2 criteria of the 3: dominant stricture, weight loss of >10% body mass index, or recidivating cholangitis for PSC). Patients who receive MELD exceptions are awarded an initial MELD score that ranges from an equivalent of a mortality of 10% at 3 months (20 points) for PCLD or cystic fibrosis to an equivalent of a mortality of 25% at 3 months (25 points) for PPH. Most MELD exceptions (HCC, familial amyloid polyneuropathy, hepatopulmonary syndrome (HPS), HHT, HEHE) initially receive an exceptional MELD score equivalent to a mortality of 15% at 3 months (22 points). Exceptional MELD scores for the above conditions increase by 2-3 points equivalent to an additional 10% of mortality every 3 months as long as the defining condition persisted. Patients with SE for BS and persistent graft dysfunction are granted additional points corresponding to an increase of 20% mortality at 3 months over their calculated laboratory MELD score that can be upgraded at any time. For PSC, the same was applied until March 2012, when the calculation of exceptional MELD scores for PSC was changed to a timedependent system starting with 22 points, corresponding to 15% mortality at 3 months with increases corresponding to a further 10% mortality at 3 months' intervals. Except for this change and minor textual clarifications, MELD exceptions remained unaltered until 2016.
DATA COLLECTION AND DEFINITION OF ENDPOINTS
Wait-list data of all patients listed in the ET area for deceased donor transplant since introduction of MELD score-based allocation in December 2006 until December 2015 were extracted from ET International Foundation's mainframe database. Use of anonymized data was approved by the Eurotransplant Liver Advisory Committee.
Pediatric patients, patients transplanted with a highurgency status (acute liver failure, primary graft nonfunction, and so on), and patients transplanted with a living donor organ were excluded from the analysis. Transplantations using livers from donation after circulatory death (DCD) constitute approximately 10% of liver transplantations in Belgium and the Netherlands (8) but are not performed in Germany. DCDs were not excluded from this analysis because these organs are allocated according to the same algorithms as organs from brain-dead donors with the exception that they are never exchanged between Belgium and the Netherlands on the one side, and Germany on the other.
To evaluate the effect of SE-and NSE-driven allocation on wait-list outcomes, we defined a positive wait-list outcome (patient transplanted or delisted as recovered) and a negative wait-list outcome (patient died on the waiting list or delisted as too sick for transplant). We chose this binary endpoint as a best approximation for intended and unintended outcomes, respectively, under the condition of an allocation system aiming at equity in urgency-based donor organ allocation. Urgency-based donor liver allocation aims at averting death under the constraint of severe donor organ scarcity. In contrast, time alive on the waiting list is not a relevant factor in this perspective. Therefore, a time-to-event analysis (ie, according to waiting time) was not performed. Patients taken from the waiting list as recovered were not censored but were included as a positive outcome because they were subject to the MELD-based allocation system during their time on the waiting list and, initially, were judged to have an indication for liver transplantation.
STATISTICAL ANALYSIS
Data were analyzed using R, version 3.2.0 (R Foundation for Statistical Computing, Vienna, Austria) and IBM SPSS, version 23 for Mac (IBM Corporation, Armonk, NY). The distribution of continuous data is presented by mean 6 standard deviation or median and interquartile range (25th to 75th percentiles) depending on whether visual inspection of histograms revealed major deviations from the normal distribution. Respective group comparisons were performed by t tests or Mann-Whitney U tests, respectively. Categorical data are presented by absolute and relative frequencies and were compared between groups using the chisquare or Fisher's exact test as appropriate.
Model-based recursive partitioning (MOB) was employed to assess whether the relation of matched MELD scores to the endpoint, as estimated by a logistic regression model, was stable across countries and SE categories. The country of transplantation was expected to be a possible confounding factor, as donor rates differ between ET countries. This was expected to lead to different MELD scores at organ allocation and to affect the relation between exceptional MELD score categories and negative outcome.
MOB tests for instability of the model's parameters over a set of variables, here "country" and "SE categories." The variable associated with the most significant parameter instability is used to split the data into 2 subsets. The split is conducted among the values of the respective variable and is chosen to optimize the fits of 2 models built within the resulting subsets. The procedure is repeated until testing for instabilities in the respective model parameters no longer reaches statistical significance. (9) The final result is 2-fold: (1) it provides a set of individual regression models defined in subsets, ie, patient subgroups, (2) which themselves are defined by split rules in the investigated variables.
Survival after transplantation was estimated using Kaplan-Meier statistics with a follow-up of 3 years. Patients lost to follow-up or not having reached the follow-up time were censored. Patients were grouped according to their exception status, and Kaplan-Meier curves were compared with respect to these factors with a log-rank test.
Results
From December 2006 until December 2015, 24,416 patients left the ET liver waiting list. A total of 6910 patients were excluded from the analysis because they were on the waiting list in countries without MELDbased direct allocation, were pediatric patients, or were patients qualifying for high-urgency transplants (mainly acute liver failure or liver graft failure); 17,506 patients in the countries with MELD-based direct allocation fulfilled the inclusion criteria (Germany, n 5 13,494; Belgium, n 5 2603; the Netherlands, n 5 1409). Of the included patients, 3548 patients left the waiting list with SEs. The most common reason for a SE was HCC (70.8%), followed by PSC with 8.2%, BS and PcLD with 6.3% each (Table 1) . Also, 330 patients had NSEs. Of all included patients, 10,201 (58.3%) underwent transplantation, 1379 (7.9%) were taken from the waiting list as recovered, 4051 (23.1%) died on the waiting list, and 1295 (7.4%) were delisted as unfit for transplant. Consequently, 16,926 patients had either a positive or negative wait-list outcome as defined above. Outcome was positive in 11,580 of these patients (8598 or 63.1% of those without any MELD exception, 2715 or 76.5% of those with SEs, 267 or 90.1% of those with NSEs) and negative in 5346 patients (4493 without NSEs or SEs, 2715 with SEs, and 61 with NSEs).
The proportion of transplanted patients with NSEs more than doubled from 1.8% in 2007 to 3.9% in 2015. The proportion of transplanted patients with SEs peaked in 2011 at 37.7% (Fig. 1) . A negative outcome on the waiting list was significantly and relevantly more common among patients without SE or NSEs (34.3%) than among patients with SE (22.6%) or NSE (18.6%; P < 0.001). The proportion of negative versus positive wait-list outcomes for different SEs and for patients without exceptional MELD are presented in Fig. 2 . Negative wait-list outcome was significantly more frequent in Germany (34.4%) compared Table 2 ; 2745 donor organs (14.7%) were not allocated to individual patients directly but to the transplant centers as rescue allocations. These organs were then allocated by the centers according to internal decisions, and 16.0% of patients with no exceptional MELD and 15.4% of patients with SEs received organs allocated by the centers (NS; P 5 0.38). The proportion among patients with NSEs, however, was significantly lower (7.0%, P < 0.001). According to diagnostic groups, the largest proportion of center allocations occurred among patients with cholangiocarcinoma, where 45.5% of patients without SEs and 72.7% of patients with SEs received an organ allocated by the center. In all other groups, the proportion of patients receiving a center allocation was lower among those with SEs compared with those without SEs.
Patients with cirrhosis and no SE received a rescue allocation in 35% of all transplants. Proportions in all other diagnostic groups were lower for patients without SEs and again lower for patients with SEs. Statistical analysis by MOB identified 5 subgroups according to factors interfering with the association between a negative outcome and matched MELD. In a first step, different risk models were identified according to the countries: Germany versus Belgium and the Netherlands (P < 0.001). These risk groups were again divided according to the presence and type of SE. In Germany, patients without a SE and with a SE for BS fared worst. Patients with a SE for HCC, HPS, and PPH had a significantly lower risk for an adverse outcome (P < 0.001). Wait-list outcome of patients with a SE for PSC and PcLD was best (P < 0.001). In Belgium and the Netherlands, patients with NOTE: Data are given as median (range).
FIG. 2.
Proportions of patients with negative and positive wait-list outcome according to NSE or no SE.
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no SE or SEs for HPS and PPH had a significantly worse wait-list outcome than patients with SE for BS, HCC, PcLD, and PSC (P < 0.001). The estimated relation of laboratory MELD to the probability of a negative outcome is illustrated for each group in Fig. 3 and Table 3 .
CIRRHOSIS ONLY
Of 8603 patients with cirrhosis of any etiology without MELD exceptions, 28.8% died while on the waiting list and 6.0% were taken from the list as unfit for transplantation; also, 50.9% underwent transplantation, and 9.6% were delisted as recovered.
HEPATOCELLULAR CARCINOMA
Of all 3097 patients with HCC, 2962 had cirrhosis and 135 had a noncirrhotic liver. Of all HCC patients, 1780 (57.5%) had a SE, 20 (0.6%) had a NSE, and 1297 (41.9%) had no exceptional MELD. Among those with SEs, 1306 (73.4%) underwent transplantation, as were 834 patients without SE (64.3%). Patients transplanted with SEs received an organ that was allocated to the center (instead of directly to the patient) in 21.1%, whereas this was more often the case for patients without SEs (34.5%; P < 0.001).
Outcome and MELD scores at allocation according to categories of exception status are presented in Table 4 .
PRIMARY SCLEROSING CHOLANGITIS
The second most common SE was that for PSC. Of all 969 PSC patients, 303 had a SE and 68 a NSE. In contrast to patients with HCC, proportions of patients being transplanted after center allocation were not significantly different between patients with SE compared with those transplanted without SE. Outcome and MELD scores at allocation according to categories of exception status are presented in Table 5 .
OUTCOME AFTER TRANSPLANTATION
A total of 2549 patients had died 3 years after transplantation. There were no follow-up data of 3027 patients. The probability of survival at 3 years was estimated at 67.7% 6 0.5%. It was 66.9% 6 0.6% for patients without a SE and 69.7% 6 1.1% for patients with a SE (P 5 0.001).
Discussion
Our analysis shows that wait-list outcomes for patients in need of liver transplantations in the MELD countries of the ET area are considerably better in the Netherlands and Belgium compared with Germany. Correcting for that difference, patients with NSEs and some SEs have a decisively superior wait-list outcome compared with patients without MELD exceptions. Among transplanted patients, about a third are registered with either SEs or NSEs, a figure that is similar to those reported from the United States. (5) Especially patients with SEs for HCC and PSC, which together account for 16% of all patients, have a considerably lower risk of an adverse outcome on the waiting list.
A limitation of the study is that laboratory MELD scores on the waiting list may not exactly reflect actual MELD scores of patients at the exact time point of leaving the waiting list, because laboratory values are not reported on a day-by day-basis but after specified intervals. Typically, transplant centers update information on deteriorating patients instantaneously but may wait until prompted if patients' MELD scores are improving. Consequently, there may be a tendency toward overestimation of laboratory MELD scores and, consequently, of mortality risk, especially of patients with cirrhosis with fluctuating MELD scores. However, this possible confounder would work in the opposite direction of our findings.
Disparities in wait-list outcome between countries with different donor rates are not surprising. They may NOTE: Data are given as median (range) and n (%). Differences to 100% are due to wait-list outflow due to error, transplantation outside ET, delisting for noncompliance, and so on. The match MELD score is the highest value of either laboratory MELD or exceptional MELD. NOTE: Data are given as median (range) and n (%). Differences to 100% are due to wait-list outflow due to error, transplantation outside ET, delisting for noncompliance, and so on. The match MELD score is the highest value of either laboratory MELD or exceptional MELD.
be partly explained by different structures of transplant services and by important differences in donor organ availability between countries, which, for example, translate into significantly higher MELD scores at allocation in Germany compared with Belgium and the Netherlands. Within the ET area, donor organ exchanges between countries are balanced so that national differences in donor rates are not equilibrated across the region. This political decision apparently was made to avoid conflicts between countries with higher and lower donor rates. Two possible risks may thus have been addressed (10) : first, crowding out of donors in donor-rich countries who might feel exploited if more organs were leaving their country then were coming back; and second, free rider issues in countries with low donor rates because transplant services may satisfy their needs abroad and they, as well as possible donors or their relations, might thus feel less inclined to procure or offer organs for transplantation. These normative regulations, however, were not in the focus of this study, and the outcome differences between countries are not discussed further.
The sickest-first principle aims to prioritize those patients in the worst conditions to reduce mortality on the waiting list. With increasing scarcity of donor organs, however, average MELD scores at transplantation have been increasing. Consequentially, the risk of complications or death on the waiting list has increased too. Some complications may render transplantation impossible or patients may deteriorate too quickly and die before a donor organ is available.
MELD exceptions have been introduced to match the ranking on the waiting list of those patients whose mortality risk is not represented by laboratory MELD scores to the urgency-based ranking of patients with cirrhosis according to their laboratory MELD scores.
(5) Some SEs, however, seem to overshoot this aim. As an overall result, in the ET MELD countries, patients without SEs seem to be unintentionally disadvantaged concerning deceased donor liver allocation.
Patients with HCC constitute the largest group of patients with SEs. Interestingly, 42% of patients with HCC, who left the waiting list, had no SE. Twothirds of these received a liver transplant and had a median laboratory MELD score of 10. Transplantation at these low MELD scores was facilitated by a higher proportion of (rescue) allocations to the centers and not as MELD-based direct allocations in these patients. It therefore seems possible that centers tried to counterbalance a perceived misallocation of donor organs by the MELD system through an increased use of center allocations for patients who had an HCC but did not qualify for SEs. From our data, we cannot determine why these patients with HCC did not qualify for MELD exceptions, for example, if they had HCC beyond the Milan criteria or HCC Barcelona Clinic Liver Cancer score 0. It should be further investigated, if prioritization of these patients within centers occurs based on the assumption that current limitation of HCC SE to patients with HCC within the Milan criteria are too restrictive, given the good posttransplant prospects of patients with larger tumor loads. (11, 12) In effect, even among patients with HCC but without SEs, the proportion that received a liver transplant was substantially higher than among patients with cirrhosis.
Among patients with PSC, those not qualifying for a SE also had considerably better wait-list outcomes than patients with cirrhosis. The difference was even more pronounced than in the case of patients with HCC. This mirrors findings from the United Network for Organ Sharing area. (13) The proportion of center allocations, however, was not increased in PSC patients without SEs compared with patients with SEs. Therefore, the increased likelihood of a positive wait-list outcome seems to be related to the more benign and stable course of the disease. In summary, we not only find a considerably better wait-list outcome of patients with HCC or PSC and SEs, compared with patients with cirrhosis without SEs, but also of patients without SEs, who still have superior outcomes compared with patients with cirrhosis. This occurs despite center allocations that-with the exception of cholangiocarcinoma-tended to ameliorate the disparities of allocation between patients with and without SE by preferentially allocating organs to patients without SE.
The mode of rescue allocations has been revised in 2013. The intention was to implement the sickest-first principle based on the matched MELD score also in the allocation of organs that have to be allocated quickly. This revised mode is referred to as extended allocation. Thus, the centers' discretion at allocating these organs to patients, who are not prioritized by the MELD system, has been reduced. Since then, the relation of patients with SEs to patients without SEs, who are transplanted with organs using this mode of extended allocation has increased, compared with the previous mode of center allocation (data not shown).
Urgency-based allocation through the MELD system has been criticized in the past as posttransplant survival of those patients with the highest MELD scores has been found to be inferior to that of patients who are transplanted at lower MELD scores. (14) This is compatible with our additional finding that in the group of patients with SEs not only wait-list mortality was lower than in those patients with no MELD exceptions, but also survival after transplantation was superior, albeit by a small margin. The tacit expectation of a better outcome may also have led centers to preferentially transplant patients with HCC or PSC even if they had no MELD exception compared with patients with cirrhosis by using organs allocated to the centers by the now obsolete mode of center allocation.
A more outcome-oriented allocation of donor organs has been demanded from an utilitarian perspective, (15, 16) which might be seen as a justification to accept the above finding of a preferential allocation to patients with certain MELD exceptions who supposedly may have longer survival after liver transplantation. However, aggregate survival per transplanted organ has been questioned as an adequate measure of outcome, because it does not adequately reflect the gain in aggregate lifetime achieved by each donor organ as compared with the natural progression of the disease. (15, 17) More importantly, this deviation from the intended urgency-based allocation is not founded on explicit normative decision.
To accept this effect, an open and transparent discussion regarding the trade-off between urgency-based and utility-oriented allocation would be necessary. Many stakeholders may be interested, and fundamental legal aspects in all ET countries will be concerned.
In 2000, the ministers responsible for public health of the then 6 member states of the ET region signed a basic document specifying the aims of the allocation system. They declared "the most important factor is to maximize equality of opportunity for patients, and to do so by taking into account objective medical criteria." (18) We believe that under the condition of persistent scarcity of donor organs, urgency-based allocation best assures this equality of opportunity of patients on the waiting list.
Therefore, in the light of the present empirical data, a revision of current regulations for SEs and NSEs should be initiated, even if a perfect match of risks on the waiting list across different diagnostic groups may be impossible to achieve because of their different temporal dynamics regarding the risks of mortality and progression beyond the possibility of transplantation.
As far as SEs are concerned, matched MELD scores that increase in a time-dependent fashion, without corresponding increases of the mortality risks, should be changed in the future, to avoid "MELD score inflation." Lower entry-level matched MELD scores and a slower MELD progression might help to adapt scores to the actual risks of death on the waiting list or dropout due to disease progression. For PSC, a return to matched MELD scores as a percent increment on laboratory MELD, as applied in the Netherlands, may reflect the variable progression (19) (20) (21) (22) of the disease better than the time-dependent MELD increases that have been introduced in Germany in 2013.
NSEs were associated with the best wait-list outcome in our study. In Germany, Belgium, and the Netherlands, centers can request NSEs for recipients not eligible for a SE and not well stratified by their laboratory MELD. There are no formal prerequisites for obtaining a NSE, instead, upon request, an audit process has to be passed, upon which an initial MELD score equivalent to 15% (Germany) or 10% (Belgium and the Netherlands) 90-day mortality is granted. This NSE has to be reapproved every 90 days upon which additional MELD points corresponding to an increase of 10% of 90-day mortality are added. Our data suggest that this procedure leads to a gross overestimation of the patients' actual mortality risk. Therefore, the application of NSEs should be more standardized and restricted and the allotted MELD scores should be reduced.
In conclusion, our analysis shows that patients with SEs and NSEs have a substantially better outcome on the waiting list than patients without SEs in the ET MELD countries. We believe this prioritization is unintended and not justified. If the aim of equitable access to donor organs and equitable risk of adverse outcomes on the waiting list for all patients qualifying for liver transplantation is to be upheld, modification of SEs should be initiated and the application of NSEs should be considerably reduced.
